CNNFDA advisers vote in support of Paxlovid approval for Covid-19 treatment in high-risk adultsMar 17, 2023Janelle C ChavezBy Janelle C Chavezmore_vert
CNBCFDA staff report says data shows Pfizer's Covid treatment Paxlovid is effective in high-risk adultsMar 14, 2023Annika Kim ConstantinoBy Annika Kim Constantinomore_vert
AxiosFDA: Paxlovid not associated with COVID reboundMar 14, 2023Sabrina MorenoBy Sabrina Morenomore_vert
ReutersPfizer's COVID drug data supports use in high-risk patients - FDA staff (March 14)Mar 15, 2023Leroy Leo & Khushi MandowaraBy Leroy Leo & Khushi Mandowaramore_vert
The New York TimesF.D.A. Advisers Endorse Paxlovid's Benefits as a Covid Treatment (Published 2023)Mar 16, 2023Christina Jewett & Carl ZimmerBy Christina Jewett & Carl Zimmermore_vert
CNBCFDA advisors recommend full approval of Pfizer Covid treatment Paxlovid for adults 50 and over and other high-risk peopleMar 16, 2023Annika Kim ConstantinoBy Annika Kim Constantinomore_vert